DE60123458D1 - Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden - Google Patents

Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden

Info

Publication number
DE60123458D1
DE60123458D1 DE60123458T DE60123458T DE60123458D1 DE 60123458 D1 DE60123458 D1 DE 60123458D1 DE 60123458 T DE60123458 T DE 60123458T DE 60123458 T DE60123458 T DE 60123458T DE 60123458 D1 DE60123458 D1 DE 60123458D1
Authority
DE
Germany
Prior art keywords
neuropeptide
receptor ligands
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60123458T
Other languages
English (en)
Other versions
DE60123458T2 (de
Inventor
Volker Breu
Frank Dautzenberg
Patrizio Mattei
Werner Neidhart
Philippe Pflieger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE60123458D1 publication Critical patent/DE60123458D1/de
Application granted granted Critical
Publication of DE60123458T2 publication Critical patent/DE60123458T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
DE60123458T 2000-11-10 2001-11-06 Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden Expired - Fee Related DE60123458T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00124610 2000-11-10
EP00124610 2000-11-10
PCT/EP2001/012818 WO2002038551A1 (en) 2000-11-10 2001-11-06 Pyrimidine derivatives and their use as neuropeptide y receptor ligands

Publications (2)

Publication Number Publication Date
DE60123458D1 true DE60123458D1 (de) 2006-11-09
DE60123458T2 DE60123458T2 (de) 2007-08-02

Family

ID=8170342

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60123458T Expired - Fee Related DE60123458T2 (de) 2000-11-10 2001-11-06 Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden

Country Status (20)

Country Link
US (1) US6657060B2 (de)
EP (1) EP1335906B1 (de)
JP (1) JP2004524279A (de)
KR (1) KR100611853B1 (de)
CN (1) CN1473156A (de)
AR (1) AR034700A1 (de)
AT (1) ATE340784T1 (de)
AU (2) AU2002227905B2 (de)
BR (1) BR0115045A (de)
CA (1) CA2427350A1 (de)
DE (1) DE60123458T2 (de)
DK (1) DK1335906T3 (de)
ES (1) ES2271100T3 (de)
MX (1) MXPA03004136A (de)
PA (1) PA8531701A1 (de)
PE (1) PE20020603A1 (de)
PT (1) PT1335906E (de)
UY (1) UY27018A1 (de)
WO (1) WO2002038551A1 (de)
ZA (1) ZA200302970B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005520821A (ja) * 2002-03-15 2005-07-14 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド ４−アミノピリミジン及び表面の抗菌処理のためのその使用
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
US7768604B2 (en) * 2005-09-20 2010-08-03 Au Optronics Corporation Transflective liquid crystal display with partially shifted reflectivity curve
AU2007204208A1 (en) * 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
US20090325957A1 (en) * 2006-08-24 2009-12-31 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
JP2010533161A (ja) * 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物−９４６
AR067478A1 (es) * 2007-07-09 2009-10-14 Astrazeneca Ab Compuestos derivados de morfolina pirimidina
EP2178866A2 (de) * 2007-07-09 2010-04-28 AstraZeneca AB Trisubstituierte pyrimidinderivate zur behandlung proliferativer krankheiten
ES2385692T3 (es) 2007-07-09 2012-07-30 Astrazeneca Ab Derivados de morfolino pirimidina usados en enfermedades relacionadas con mTOR quinasa y/o PI3K
US20110166135A1 (en) * 2008-09-10 2011-07-07 Hiroshi Morimoto Aromatic nitrogen-containing 6-membered ring compounds and their use
TW201028410A (en) * 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
JP2011201873A (ja) * 2010-03-03 2011-10-13 Mitsubishi Tanabe Pharma Corp 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用
US20130237550A1 (en) * 2010-03-11 2013-09-12 Targacept, Inc. Arylvinylazacycloalkane compounds for constipation
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
WO2015039292A1 (zh) * 2013-09-18 2015-03-26 华安医学股份有限公司 一种活化ampk的化合物及其用途
CN112375042A (zh) * 2020-10-27 2021-02-19 安徽医科大学 三甲氧基苯乙烯基六元环类和吡唑并嘧啶类化合物、制剂及其制备与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH024345A (ja) * 1988-06-15 1990-01-09 Matsushita Electric Ind Co Ltd 超音波変換装置
JPH0720467B2 (ja) * 1988-06-15 1995-03-08 松下電器産業株式会社 超音波診断装置
EP0662962A1 (de) * 1992-09-28 1995-07-19 Pfizer Inc. Substituierte pyrimidinen zur kontrolle der diabetische komplikationen
JP4106711B2 (ja) 1996-03-21 2008-06-25 萬有製薬株式会社 アミノピリジン誘導体
WO1998040356A1 (fr) * 1997-03-12 1998-09-17 Banyu Pharmaceutical Co., Ltd. Medicaments contenant des derives d'aminopyridine comme ingredient actif

Also Published As

Publication number Publication date
ZA200302970B (en) 2004-07-15
AU2002227905B2 (en) 2006-10-05
CN1473156A (zh) 2004-02-04
ATE340784T1 (de) 2006-10-15
US20020086858A1 (en) 2002-07-04
JP2004524279A (ja) 2004-08-12
KR100611853B1 (ko) 2006-08-11
WO2002038551A1 (en) 2002-05-16
BR0115045A (pt) 2004-02-03
EP1335906B1 (de) 2006-09-27
AU2790502A (en) 2002-05-21
UY27018A1 (es) 2002-06-20
PT1335906E (pt) 2007-01-31
MXPA03004136A (es) 2003-08-19
ES2271100T3 (es) 2007-04-16
PA8531701A1 (es) 2003-06-30
US6657060B2 (en) 2003-12-02
EP1335906A1 (de) 2003-08-20
PE20020603A1 (es) 2002-07-20
AR034700A1 (es) 2004-03-17
CA2427350A1 (en) 2002-05-16
DE60123458T2 (de) 2007-08-02
DK1335906T3 (da) 2007-02-05
KR20040004432A (ko) 2004-01-13

Similar Documents

Publication Publication Date Title
DE60112322D1 (de) Aminothiazole und deren verwendung als adenosinrezeptorantagonisten
ATE394102T1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
DE60001840T2 (de) Chinuclidin-derivate und deren verwendung als muscarin-m3-rezeptoren-liganden
DE60129841D1 (de) Indolderivate und deren verwendung als 5-ht2b- und 5-ht2c-rezeptorliganden
DE60009116D1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE60005386D1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
ATE309224T1 (de) Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren
ATE375987T1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE60113719D1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
ATE323079T1 (de) Neue sulfamiden und deren verwendung als endothelin-antagonisten
ATE301638T1 (de) 3-arylindolderivate und deren verwendung als cb2- rezeptoragonisten
ATE340784T1 (de) Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden
ATE348805T1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE60139477D1 (de) 2-cyanopyrrolidin-derivate und ihre verwendung als arzneimittel
ATE280158T1 (de) 3-phenylpyridinderivative und deren verwendung als nk-1 rezeptorantagonisten
DE60135239D1 (de) Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden
DE60106607D1 (de) Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
ATE273283T1 (de) Diphenylharnstoffderivate und deren verwendung als alpha2/5-ht2c antagonisten
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
ATE283844T1 (de) Pyrimidinverbindungen und deren verwendung als pestizide
DE50105955D1 (de) Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren
ATE551329T1 (de) Chinazolinonderivate und deren verwendung als cb- agonisten
DE60021507D1 (de) Uracilverbindungen und deren Verwendung
DE50113867D1 (de) Neue indolderivate und deren verwendung als arzneimittel
DE50206476D1 (de) Cyanoanthranylamid-derivate und deren verwendung als arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee